Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Valuable Targets
7 min read
T-cell co-stimulation target: 4-1BB (CD137)
10 November 2023
4-1BB (also known as CD137 or TNFRSF9) was first discovered in 1989 and is a critical co-stimulation receptor on T cells and other immune cells.
Drug Insights
4 min read
An In-depth Analysis of Penicillin G Procaine's R&D Progress and Mechanism of Action on Drug Target
10 November 2023
This article summarized the latest R&D progress of Penicillin G Procaine, the Mechanism of Action for Penicillin G Procaine, and the drug target R&D trends for Penicillin G Procaine.
Latest Hotspot
3 min read
Abbisko Therapeutics' FGFR4 inhibitor, ABSK012, has received FDA clinical trial approval for the treatment of advanced solid tumors
10 November 2023
Abbisko Therapeutics recently reported that its self-developed small molecule FGFR4 inhibitor ABSK012, aimed at drug-resistant mutations, has received FDA approval to begin phase I human trials with advanced solid tumor patients.
Drug Insights
4 min read
Pentobarbital Sodium: Detailed Review of its Transformative R&D Success
10 November 2023
This article summarized the latest R&D progress of Pentobarbital Sodium, the Mechanism of Action for Pentobarbital Sodium, and the drug target R&D trends for Pentobarbital Sodium.
Valuable Targets
6 min read
Latest Research Progress on TLR Adjuvants
10 November 2023
The TLR agonists used in vaccine formulations come in various forms, ranging from lipopeptides to single-stranded DNA and RNA.
Drug Insights
4 min read
A Comprehensive Review of Nepafenac's R&D Innovations and Drug Target Mechanism
10 November 2023
This article summarized the latest R&D progress of Nepafenac, the Mechanism of Action for Nepafenac, and the drug target R&D trends for Nepafenac.
Latest Hotspot
3 min read
The phase 2 clinical trial results of MoonLake's innovative nanobody treatment, Sonelokimab, have shown positive outcomes, effectively alleviating psoriasis
10 November 2023
MoonLake Immunotherapeutics recently announced positive results from the global Phase 2 clinical trial, ARGO, assessing the efficacy and safety of its nanobody, sonelokimab, in patients with active psoriatic arthritis (PsA).
Drug Insights
4 min read
Pharmaceutical Insights: Nemolizumab's R&D Progress and its Mechanism of Action on Drug Target
10 November 2023
This article summarized the latest R&D progress of Nemolizumab, the Mechanism of Action for Nemolizumab, and the drug target R&D trends for Nemolizumab.
Advanced Tech.
6 min read
Highly Efficient Treatment for Killing Drug-Resistant Bacteria: Bacteriophage Therapy
10 November 2023
Challenging the pathogenicity of bacteria through Bacteriophage therapy could lead the way to improved antibiotic strategies.
Drug Insights
5 min read
ExploringMycophenolate Sodium's Revolutionary R&D Successes and its Mechanism of Action on Drug Target
10 November 2023
This article summarized the latest R&D progress of Mycophenolate Sodium, the mechanism of action for Mycophenolate Sodium, and the drug target R&D trends for Mycophenolate Sodium.
Valuable Targets
6 min read
New Generation Vaccine Adjuvant: TLR Agonists
10 November 2023
TLRs are innate immune receptors that are responsible, directly or indirectly, for detecting pathogen-associated molecular patterns (PAMPs) and responding to them through the activation of innate and adaptive immune pathways.
Latest Hotspot
3 min read
Molecular Templates has begun Phase 1 dosing of MT-8421, a distinct engineered toxin body targeting CTLA-4, for advanced solid tumor treatment
10 November 2023
Molecular Templates has commenced dosing in Phase 1 trial of MT-8421, a unique engineered toxin body targeting CTLA-4, for treating advanced solid tumors.